Literature DB >> 8142658

Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization.

M Bentz1, G Cabot, M Moos, M R Speicher, A Ganser, P Lichter, H Döhner.   

Abstract

The presence of BCR-ABL fusion genes has important diagnostic and prognostic implications in chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The CML-specific chimeric BCR-ABL gene with a break involving the major breakpoint cluster region (M-bcr) of the BCR-gene has been detected by means of fluorescence in situ hybridization (FISH). In this study, we present a FISH protocol that allows the detection of breaks in both the major and the minor breakpoint cluster region (m-bcr). Three hybridization signals of D107F9, a yeast artificial chromosome (YAC)-derived probe spanning the breakpoint regions of the BCR gene, were indicative of the translocation events. To increase the specificity further, this probe was combined with cos-abl 8, a cosmid probe flanking the breakpoint within the ABL gene for dual-color hybridization. Samples of 21 patients with CML, the ALL-derived cell line SUP-B15, and of seven patients with Philadelphia chromosome (Ph1)-positive ALL (three of them with breakpoints within m-bcr) were examined. BCR-ABL fusion was detected in all cases with high specificity (false-positive nuclei: mean, 0.1%). On cytogenetic preparations, the percentages of BCR-ABL-positive interphase cells ranged from 53% to 91%. Comparable efficiencies were achieved on blood smears. In conclusion, hybridization with D107F9 and cos-abl 8 allows unambiguous diagnosis of BCR-ABL genes and is likely to become an important tool for the monitoring of therapies in patients with CML and ALL.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8142658

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood.

Authors:  You Kyoung Lee; Dong Wha Lee; Yoo Li Kim; Seok Lee; Chang Ki Min; Yoo-Jin Kim; Il-Hoan Oh; Tai-Gyu Kim; Chun Choo Kim; Dong-Wook Kim
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  [Fluorescence in-situ hybridization (FISH). Method and application].

Authors:  K Fischer; M Bentz; H Döhner
Journal:  Med Klin (Munich)       Date:  1997-05-15

3.  Molecular cytogenetic delineation of a novel critical genomic region in chromosome bands 11q22.3-923.1 in lymphoproliferative disorders.

Authors:  S Stilgenbauer; P Liebisch; M R James; M Schröder; B Schlegelberger; K Fischer; M Bentz; P Lichter; H Döhner
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

4.  Analysis of repetitive DNA in chromosomes by flow cytometry.

Authors:  Julie Brind'Amour; Peter M Lansdorp
Journal:  Nat Methods       Date:  2011-05-01       Impact factor: 28.547

5.  ChiPPI: a novel method for mapping chimeric protein-protein interactions uncovers selection principles of protein fusion events in cancer.

Authors:  Milana Frenkel-Morgenstern; Alessandro Gorohovski; Somnath Tagore; Vaishnovi Sekar; Miguel Vazquez; Alfonso Valencia
Journal:  Nucleic Acids Res       Date:  2017-07-07       Impact factor: 16.971

6.  Double-staining chromogenic in situ hybridization as a useful alternative to split-signal fluorescence in situ hybridization in lymphoma diagnostics.

Authors:  Anke van Rijk; Tim Svenstroup-Poulsen; Margaret Jones; José Cabeçadas; Juan Cruz Cigudosa; Lorenzo Leoncini; Anja Mottok; Christiane Copie Bergman; Evi Pouliou; Stephen Hamilton Dutoit; Han J van Krieken
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

7.  [Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].

Authors:  J Thiele; H M Kvasnicka; E Varus; S Kriener; K Engels; P Staib; E S Ollig; M Griesshammer; C F Waller; H Pfeifer; A Schmitt-Gräff
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

8.  Correlation between BCR-ABL expression and tumor burden is restricted to the transition from minor to major cytogenetic response in interferon treated CML patients.

Authors:  László Kereskai; János A Vass; Mária Kneif; László Pajor
Journal:  Pathol Oncol Res       Date:  2003-10-07       Impact factor: 3.201

9.  Interphase Molecular Cytogenetic Detection Rates of Chronic Lymphocytic Leukemia-Specific Aberrations Are Higher in Cultivated Cells Than in Blood or Bone Marrow Smears.

Authors:  Eyad Alhourani; Rouben Aroutiounian; Tigran Harutyunyan; Anita Glaser; Cordula Schlie; Beate Pohle; Thomas Liehr
Journal:  J Histochem Cytochem       Date:  2016-06-17       Impact factor: 2.479

10.  Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation.

Authors:  S Fujii; K Shimizu; K Fujimoto; T Kiyokawa; T Shimomura; M Kinoshita; F Kawano
Journal:  Jpn J Cancer Res       Date:  1999-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.